Exploration and practice of post-marketing survival benefit evaluation of Chinese patent medicine for cancer.
10.19540/j.cnki.cjcmm.20210205.502
- Author:
Bo-Wen XU
1
;
Jing-Yuan WU
1
;
Jie LI
2
;
Ying ZHANG
2
;
Lu-Chang CAO
2
;
Xiao-Xiao ZHANG
2
;
Rui-Ke GAO
2
Author Information
1. Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China Beijing University of Chinese Medicine Beijing 100029, China.
2. Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
dominant population;
evaluation system;
post-marketing evaluation;
survival benefit;
tumor
- MeSH:
China;
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Marketing;
Medicine, Chinese Traditional;
Neoplasms/drug therapy*;
Nonprescription Drugs/therapeutic use*;
Quality of Life
- From:
China Journal of Chinese Materia Medica
2021;46(8):1980-1987
- CountryChina
- Language:Chinese
-
Abstract:
Traditional Chinese medicine(TCM) is an important feature of cancer treatment in China. The methods to tap the advantages of TCM, reasonably evaluate and accurately apply Chinese patent medicines have become current research hotspots and difficulties. TCM takes syndrome differentiation and treatment as the core, with the characteristics of overall regulation and multi-targets efficacy. Therefore, the post-marketing survival benefit evaluation of Chinese patent medicines for cancer is different from that in modern medicine. The primary treatment goals in cancer patients include to improve the disease control rate and prolong their survival time. At present, Chinese patent medicines for cancer patients are lacking indepth studies on survival benefit at the post-marketing stage. In addition, the characteristics of individualized treatment with TCM have also increased the complexity of clinical research on TCM. Therefore, it is of certain practical significance and necessity to evaluate the survival benefit of Chinese patent medicines for cancer after marketing. Based on this, in this paper, we first summarized the technical methodological means of survival benefit evaluation at this stage, and then explored the post-marketing survival benefit evaluation of Chinese patent medicines for cancer from three aspects: the evaluation of cancer treatment effect based on survival time and quality of life, treatment-related toxicity and the auxiliary effect of TCM, and the improvement effect for tumor-related symptoms. Based on the practices of early clinical researches, and according to the insufficient efficacy evaluation of current clinical research on Chinese patent medicines, this paper proposed to improve the evaluation system for clinical researches on Chinese patent medicines, establish the evaluation method with TCM characteristics, clarify the dominant population, lay a theoretical foundation for the evaluation of post-marketing survival benefits of Chinese patent medicines for cancer in the future, and promote the modernization process of TCM.
